Paper Details

  1. Home
  2. Paper Details

Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.

Author: GaoHong-wei, HongTian-pei, LinYu-jing, WangHai-ning, XieChao

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nateglinide acutely decreased postprandial free fatty acids (FFA) and asymmetric dimethylarginine (ADMA) levels more significantly than acarbose in patients with newly-diagnosed type 2 diabetes. These reductions may be associated with the partial restoration of early-phase insulin secretion and could offer cardiovascular benefits.
Paper Details　
Original Abstract of the Article :
AIM: To investigate the acute and chronic effects of nateglinide versus acarbose on plasma asymmetric dimethylarginine (ADMA) levels and lipid profiles in patients with newly-diagnosed type 2 diabetes. METHODS: A crossover trial of nateglinide and acarbose was conducted on 16 drug-naïve patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1745-7254.2007.00534.x

データ提供：米国国立医学図書館（NLM）

Managing Type 2 Diabetes: Nateglinide vs Acarbose

Type 2 diabetes is a chronic condition characterized by high blood sugar levels. This research compared the effects of two medications, nateglinide and acarbose, in managing newly diagnosed type 2 diabetes. The study involved 16 drug-naive patients with type 2 diabetes who received both medications in a crossover trial. The results showed that nateglinide was more effective than acarbose in acutely decreasing postprandial free fatty acids (FFA) and asymmetric dimethylarginine (ADMA) levels, suggesting potential cardiovascular benefits of nateglinide.

A Heart-Healthy Choice: Nateglinide for Diabetes Management

This research provides evidence for the potential cardiovascular benefits of nateglinide in managing type 2 diabetes.

A Healthy Lifestyle: Managing Diabetes

This research highlights the importance of early intervention and appropriate medication in managing type 2 diabetes.

Dr.Camel's Conclusion

This research is like a compass guiding us through the complex landscape of diabetes management, highlighting the potential of nateglinide in improving cardiovascular health.

Date :
  1. Date Completed 2009-04-30
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17376293

DOI: Digital Object Identifier

10.1111/j.1745-7254.2007.00534.x

Related Literature

Article Analysis
・Effects of nateglinide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.